Myocardial amiodarone and desethylamiodarone concentrations in patients undergoing cardiac transplantation.

J Am Coll Cardiol

Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032.

Published: October 1990

Myocardial amiodarone and desethylamiodarone concentrations were measured at multiple sites in the explanted heart in four patients who underwent cardiac transplantation. Patients were taking amiodarone, 200 to 400 mg/day (mean 300 +/- 115), for 88 to 428 days (mean 229 +/- 148). The mean cumulative dose was 58 +/- 21.3 g. Plasma amiodarone concentration in three subjects was 204, 312 and 419 ng/ml and desethylamiodarone concentration was 268, 513 and 880 ng/ml, respectively. Significant interindividual variability in myocardial concentrations of amiodarone and desethylamiodarone was observed (p less than 0.05). Mean myocardial amiodarone concentration ranged from 4 +/- 1.0 to 29 +/- 17.2 micrograms/g (p less than 0.05); mean desethylamiodarone concentration ranged from 22 +/- 8.8 to 141 +/- 102.5 micrograms/g (p less than 0.05). At each site, save for fat, myocardial desethylamiodarone concentration was higher than amiodarone concentration. Greater intraindividual variability was observed in myocardial desethylamiodarone compared with amiodarone concentration particularly in septal and scar tissue (p = NS). No significant relation was found between myocardial concentration and duration of treatment. In patients with significant ventricular disease, usefulness of plasma amiodarone and desethylamiodarone concentration to estimate myocardial concentration is limited by intra- and interindividual variability.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0735-1097(10)80346-8DOI Listing

Publication Analysis

Top Keywords

amiodarone desethylamiodarone
16
amiodarone concentration
16
desethylamiodarone concentration
16
myocardial amiodarone
12
concentration
10
myocardial
8
desethylamiodarone
8
desethylamiodarone concentrations
8
cardiac transplantation
8
amiodarone
8

Similar Publications

Previously, we have demonstrated that amiodarone (AM), a widely used antiarrhythmic drug, and its major metabolite desethylamiodarone (DEA) both affect several mitochondrial processes in isolated heart and liver mitochondria. Also, we have established DEA's antitumor properties in various cancer cell lines and in a rodent metastasis model. In the present study, we compared AM's and DEA's mitochondrial and antineoplastic effects in a human triple-negative breast cancer (TNBC) cell line.

View Article and Find Full Text PDF
Article Synopsis
  • The study aims to create a decision tree model to identify heart failure patients needing therapeutic drug monitoring (TDM) for high levels of mono-desethylamiodarone (MDEA), an amiodarone metabolite linked to tissue toxicity.
  • A retrospective cohort of 157 adults was analyzed to determine MDEA plasma concentrations, using a statistical algorithm that identified key risk factors affecting these levels.
  • Results showed that patients on more than 100 mg of amiodarone daily and with a body mass index of 22.3 kg/m² or less are at significant risk for elevated MDEA levels, suggesting the need for regular monitoring to prevent potential toxicity.
View Article and Find Full Text PDF

Development, validation and long-term evaluation of a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of amiodarone, desethylamiodarone and mexiletine in human plasma and serum.

J Chromatogr B Analyt Technol Biomed Life Sci

August 2024

Department of Pharmacy and Clinical Pharmacology, University of Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands; Medicines for Society Platform, Amsterdam UMC - University of Amsterdam, Amsterdam, The Netherlands.

Amiodarone and mexiletine are used for ventricular arrhythmias, for which a combination therapy of both anti-arrhythmic drugs (AADs) is not uncommon. Therapeutic drug monitoring (TDM) can be beneficial for clinical guidance of therapy, especially to correctly identify adverse events. Desethylamiodarone, the active metabolite of amiodarone, accumulates over time and is associated with serious adverse events.

View Article and Find Full Text PDF

Amiodarone is commonly used to prevent and treat life-threatening cardiac arrhythmias. However, it is also known to have an extensive side effect profile. A rare adverse effect of amiodarone is epididymitis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!